GlobeNewswire: Pluri Inc. Contains the last 10 of 398 releaseshttp://www.globenewswire.com/External?Length=42024-03-19T03:59:30ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2024/03/14/2846153/0/en/Pluri-Selected-as-CDMO-by-Remedy-Cell-for-Cell-Derived-Cell-Free-Drug-Manufacturing.html?f=22&fvtc=4&fvtv=10495Pluri Selected as CDMO by Remedy Cell for Cell-Derived Cell-Free Drug Manufacturing2024-03-14T11:00:00Z<![CDATA[PluriCDMO™ will support Remedy Cell in the manufacture of RC-0315 product candidate for the treatment of Idiopathic Pulmonary Fibrosis (IPF) PluriCDMO™ will support Remedy Cell in the manufacture of RC-0315 product candidate for the treatment of Idiopathic Pulmonary Fibrosis (IPF)]]>https://www.globenewswire.com/news-release/2024/03/11/2843630/0/en/Pluri-Receives-First-Ever-Patent-Approval-for-3D-Bioreactor-Technology-in-Plant-Cell-Cultivation.html?f=22&fvtc=4&fvtv=10495Pluri™ Receives First-Ever Patent Approval for 3D Bioreactor Technology in Plant Cell Cultivation2024-03-11T11:00:00Z<![CDATA[Patent helps position Pluri as a leader in cell expansion for the agtech industry with the launch of its PluriAgtech business vertical and cell-based coffee product Patent helps position Pluri as a leader in cell expansion for the agtech industry with the launch of its PluriAgtech business vertical and cell-based coffee product]]>https://www.globenewswire.com/news-release/2024/03/06/2841236/0/en/Pluri-Inc-Announces-Appointment-of-Jim-Roosevelt-Jr-to-its-Advisory-Board.html?f=22&fvtc=4&fvtv=10495Pluri Inc. Announces Appointment of Jim Roosevelt, Jr. to its Advisory Board2024-03-06T12:00:00Z<![CDATA[HAIFA, Israel, March 06, 2024 (GLOBE NEWSWIRE) -- Pluri Inc. (Nasdaq: PLUR) (TASE: PLUR) (“Pluri” or the “Company”), a leading biotech company that transforms cells into solutions that promote global wellbeing and sustainability, today announced the appointment of attorney James Roosevelt, Jr. to the Company’s Advisory Board.]]>https://www.globenewswire.com/news-release/2024/02/28/2836820/0/en/Pluri-s-Innovation-Across-Various-Industries-CEO-Updates-on-Recent-Achievements-2024-Goals.html?f=22&fvtc=4&fvtv=10495Pluri’s Innovation Across Various Industries: CEO Updates on Recent Achievements & 2024 Goals2024-02-28T12:00:00Z<![CDATA[HAIFA, Israel, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Leading biotechnology company Pluri Inc. (NASDAQ:PLUR) (TASE:PLUR) (“Pluri” or the “Company”) today issued the following update from CEO and President, Yaky Yanay:]]>https://www.globenewswire.com/news-release/2024/01/23/2813717/0/en/Step-into-the-Future-Pluri-Launches-Sustainable-Cell-Based-Coffee-as-Countermeasure-for-Global-Coffee-Crisis.html?f=22&fvtc=4&fvtv=10495Step into the Future: Pluri Launches Sustainable Cell-Based Coffee as Countermeasure for Global Coffee Crisis2024-01-23T07:00:00Z<![CDATA[HAIFA, Israel, Jan. 23, 2024 (GLOBE NEWSWIRE) -- Pluri Inc. (Nasdaq: PLUR) (TASE: PLUR) (“Pluri” or the “Company”), a leading biotech company that transforms cells into solutions that promote global well-being and sustainability, announced today that it has launched its cell-based coffee business activity, an innovative product that will potentially revolutionize the traditional coffee industry. Pluri’s cell-based coffee product is designed to address the growing global demand for sustainable, high-quality coffee at mass scale production.]]>Cells made into ground coffeeCells made into ground coffeePluri’s Cell-based coffeePluri’s Cell-based coffeehttps://www.globenewswire.com/news-release/2024/01/08/2805292/0/en/Pluri-Launches-Advanced-Global-Cell-Therapy-Contract-Development-and-Manufacturing-Organization.html?f=22&fvtc=4&fvtv=10495Pluri Launches Advanced Global Cell Therapy Contract Development and Manufacturing Organization2024-01-08T12:00:00Z<![CDATA[HAIFA, Israel, Jan. 08, 2024 (GLOBE NEWSWIRE) -- Pluri Inc. (Nasdaq: PLUR) (TASE: PLUR) (“Pluri” or the “Company”), a leading biotech company that transforms cells into solutions that promote global wellbeing and sustainability, today announced it has launched a new business division offering cell therapy manufacturing services as a Contract Development and Manufacturing Organization (CDMO): PluriCDMO™.]]>Clean Room, Pluri’s Manufacturing FacilityClean Room, Pluri’s Manufacturing Facilityhttps://www.globenewswire.com/news-release/2023/12/21/2799882/0/en/Pluri-and-Bar-Ilan-University-to-Develop-PLX-Cells-for-the-Treatment-of-Cocaine-Addiction.html?f=22&fvtc=4&fvtv=10495Pluri and Bar-Ilan University to Develop PLX Cells for the Treatment of Cocaine Addiction2023-12-21T12:00:00Z<![CDATA[HAIFA, Israel, Dec. 21, 2023 (GLOBE NEWSWIRE) -- Pluri Inc. (Nasdaq: PLUR) (TASE: PLUR) (“Pluri” or the “Company”), a leading biotech company that transforms cells into solutions that promote well-being and sustainability, announced it has signed an agreement assigning the joint patent rights to develop Pluri’s PLX cells in the treatment of cocaine addiction, to BIRAD–Research & Development Company Ltd., the commercial arm of Bar-Ilan University. Under the agreement, Bar-Ilan University via BIRAD will receive the right to further develop and commercialize PLX cells as a cocaine anti-addiction product, and Pluri is entitled to 20% revenue sharing from future sales of the product for anti-addiction.]]>PLX-PAD Cells (PAD) attenuate cocaine craving in animal model for drug addiction (level presses indicate the compulsive demand of a rat to inject cocaine intravenous)PLX-PAD Cells (PAD) attenuate cocaine craving in animal model for drug addiction (level presses indicate the compulsive demand of a rat to inject cocaine intravenous)https://www.globenewswire.com/news-release/2023/08/16/2726213/0/en/Pluri-s-PLX-R18-Increases-Blood-Cell-Counts-and-Reduces-Need-for-Transfusions-in-a-Phase-I-Study-Results-Published-in-Nature-Bone-Marrow-Transplantation.html?f=22&fvtc=4&fvtv=10495Pluri’s PLX-R18 Increases Blood Cell Counts and Reduces Need for Transfusions in a Phase I Study: Results Published in Nature Bone Marrow Transplantation2023-08-16T11:00:00Z<![CDATA[HAIFA, Israel, Aug. 16, 2023 (GLOBE NEWSWIRE) -- Pluri Inc. (Nasdaq: PLUR) (TASE: PLUR) (“Pluri” or the “Company”), a leading biotech company that transforms cells into solutions that promote wellbeing and sustainability, today announced the publication of an article titled “Placental expanded mesenchymal-like cells (PLX-R18) for poor graft function after hematopoietic cell transplantation: A phase I study” in the peer reviewed journal Nature Bone Marrow Transplantation.]]>https://www.globenewswire.com/news-release/2023/07/13/2704053/0/en/Pluri-Announces-Appointment-of-Entrepreneur-Lorne-Abony-to-Board-of-Directors.html?f=22&fvtc=4&fvtv=10495Pluri Announces Appointment of Entrepreneur Lorne Abony to Board of Directors2023-07-13T06:00:00Z<![CDATA[Abony: “Pluri’s cell expansion technology has extraordinary potential across a range of industries.” Abony: “Pluri’s cell expansion technology has extraordinary potential across a range of industries.”]]>Mr. Lorne AbonyMr. Lorne Abonyhttps://www.globenewswire.com/news-release/2023/07/11/2702294/0/en/U-S-National-Institutes-of-Health-to-Fund-4-2-Million-Contract-to-Advance-Development-of-Pluri-s-PLX-R18-in-Conjunction-with-U-S-DoD-as-a-Medical-Countermeasure-for-Hematopoietic-A.html?f=22&fvtc=4&fvtv=10495U.S. National Institutes of Health to Fund $4.2 Million Contract to Advance Development of Pluri’s PLX-R18 in Conjunction with U.S. DoD as a Medical Countermeasure for Hematopoietic Acute Radiation Syndrome2023-07-11T06:00:00Z<![CDATA[HAIFA, Israel, July 11, 2023 (GLOBE NEWSWIRE) -- Pluri Inc. (Nasdaq: PLUR) (TASE: PLUR) (“Pluri” or the “Company”), a leading biotech company that transforms cells into solutions that promote wellbeing and sustainability, today announced that it has signed a three year $4.2M contract with the U.S. National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH). Pluri will collaborate with the U.S. Department of Defense’s Armed Forces Radiobiology Research Institute (AFRRI)/Uniformed Services University of Health Sciences (USUHS) in Maryland, USA to further advance the development of its PLX-R18 cell therapy as a potential novel treatment for Hematopoietic Acute Radiation Syndrome (H-ARS). H-ARS is a deadly disease that can result from nuclear disasters and radiation exposure.]]>Nuclear Disaster and Radiation ExposureNuclear Disaster and Radiation Exposure